The clinical evaluation of flupentixol and melitracen for the treatment on the patients with post-stroke depression
- VernacularTitle:氟哌噻吨美利曲辛治疗脑卒中后抑郁52例临床观察
- Author:
Lanying JIN
;
Zhenhua WANG
- Publication Type:Journal Article
- Keywords:
Stroke;
Depression;
Flupentixol and melitracen
- From:
Chinese Journal of Postgraduates of Medicine
2012;(z2):12-14
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety offlupentixol and melitracen (deanxit) in the treatment on the patients with post-stroke depression.Methods A total of 98 patients of post-stroke depression were randomly divided and assigned to a therapy group and a control group.The two groups was given a routine treatment of stroke.The therapy group was treated with deanxit (52 patients,4 weeks).Both groups were measured by Hamilton rating scale of depression (HAMD),China stroke scale (CSS) and Barthel index(BI)before treatment and after 2 weeks and 4 weeks.Results The efficiency rate in treatment group was much higher than that in control group [86.5％ (45/52) vs.43.5％ (20/26),P ＜ 0.01].HAMD score,CSS score and BI in therapy group were better those in control group 4 weeks after treatment [(9.38 ±1.80) scores vs.(14.56 ± 2.40) scores,(15.79 ± 0.83) scores vs.(28.91 ± 1.02) scores,74.6 ± 15.4 vs.59.2 ± 14.6,P ＜ 0.05].There was obvious untoward reaction in therapy group.Conclusions It is indicated that deanxit can reduce the degree of depression and promote the neurological functional rehabilitation.It is safe and effective in the treatment of post-stroke depression.
